Literature DB >> 3512114

Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.

C C Anderson, A H Goldstone, R L Souhami, D C Linch, P G Harper, K A McLennan, M Jones, S J Machin, A M Jelliffe, J C Cawley.   

Abstract

Seventeen patients with advanced lymphoma were treated with high-dose chemotherapy with autologous bone marrow rescue. In 11 patients with non-Hodgkin's lymphoma (NHL) there were 2 complete remissions (CRs) and 2 partial remissions (PRs), and in 6 patients with Hodgkin's disease there were 5 CRs. Three patients remain well in unmaintained remission (days 874, 446 and 351), and a further 2 are alive and still receiving treatment (days 650 and 558). This type of therapy appears useful and should now be considered earlier in the course of the disease.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3512114     DOI： 10.1007/bf00256170

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  12 in total

1.  The presentation haemoglobin level in 1103 patients with Hodgkin's disease (BNLI report no. 21).

Authors:  K A MacLennan; B Vaughan Hudson; M J Easterling; A M Jelliffe; G Vaughan Hudson; J L Haybittle
Journal:  Clin Radiol       Date:  1983-09       Impact factor: 2.350

2.  High-dose cytosine arabinoside in non-Hodgkin's lymphoma.

Authors:  H Kantarjian; B Barlogie; W Plunkett; W Velasquez; P McLaughlin; S Riggs; F Cabanillas
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

3.  Bone marrow processing and cryopreservation.

Authors:  D C Linch; L J Knott; K G Patterson; D A Cowan; P G Harper
Journal:  J Clin Pathol       Date:  1982-02       Impact factor: 3.411

4.  Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow.

Authors:  G L Phillips; R H Herzig; H M Lazarus; J W Fay; S N Wolff; W B Mill; H Lin; P R Thomas; G P Glasgow; D C Shina
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

Review 5.  Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases.

Authors:  E D Thomas
Journal:  J Clin Oncol       Date:  1983-09       Impact factor: 44.544

6.  Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.

Authors:  J Laurence; M Coleman; S L Allen; R T Silver; M Pasmantier
Journal:  Ann Intern Med       Date:  1982-08       Impact factor: 25.391

7.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).

Authors:  A T Skarin; G P Canellos; D S Rosenthal; D C Case; J M MacIntyre; G S Pinkus; W C Moloney; E Frei
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

8.  Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study.

Authors:  S E Jones; P N Grozea; E N Metz; A Haut; R L Stephens; F S Morrison; J J Butler; G E Byrne; T E Moon; R Fisher; C L Haskins; C A Coltman
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

9.  Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of non-Hodgkin's malignant lymphoma with a very bad prognosis.

Authors:  T Philip; P Biron; P Hervé; L Dutou; A Ehrsam; I Philip; G Souillet; E Plouvier; A Le Mevel; N Philippe
Journal:  Eur J Cancer Clin Oncol       Date:  1983-10

10.  National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.

Authors: 
Journal:  Cancer       Date:  1982-05-15       Impact factor: 6.860
View more
  2 in total

1.  Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.

Authors:  M H Gaspard; D Maraninchi; A M Stoppa; J A Gastaut; G Michel; N Tubiana; D Blaise; G Novakovitch; J F Rossi; P J Weiller
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Fifty years of melphalan use in hematopoietic stem cell transplantation.

Authors:  Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-24       Impact factor: 5.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.